反弹效应:HIV感染者停用低剂量司美格鲁肽后发生什么
ACTG A5371研究纳入49名接受抑制性抗逆转录病毒治疗且伴代谢功能障碍相关脂肪性肝病的HIV感染者,每周皮下注射司美格鲁肽1 mg共24周,随后停药24周。前24周平均减重7.8 kg(95%CI 6.1-9.5),停药后24至48周平均体重反弹2.9 kg(95%CI 1.5-4.3),腰围和空腹血糖显著增加,血压、血脂及代谢综合征无显著变化。
要点
- HIV感染者使用低剂量司美格鲁肽24周可减重并改善心血管代谢指标。
- 停药24周后体重快速反弹,腰围和空腹血糖显著回升。
- 血压、血脂及代谢综合征在停药后无显著变化。
核心结论
- 短期低剂量司美格鲁肽在HIV感染者中带来心血管代谢获益,但停药后出现快速体重反弹和部分获益丧失,与一般人群相似。
研究设计与样本
- ACTG A5371研究纳入49名≥18岁、接受抑制性抗逆转录病毒治疗且伴代谢功能障碍相关脂肪性肝病的HIV感染者,全体接受皮下司美格鲁肽1 mg每周一次共24周,随后停药24周,在第0、24、48周测量体重和心血管代谢危险因素。
主要发现
- 前24周平均体重下降7.8 kg(95%CI 6.1-9.5),第24至48周平均体重反弹2.9 kg(95%CI 1.5-4.3)。
- 停药后腰围显著增加2.0 cm(95%CI 0.9-3.1),空腹血糖显著增加5.1 mg/dL(95%CI 0.9-9.3)。
- 停药后血压、总胆固醇、低密度脂蛋白胆固醇、甘油三酯及代谢综合征无显著变化。
临床怎么用
- 对HIV感染者使用低剂量司美格鲁肽减重时,应预期停药后体重反弹和部分心血管代谢获益丧失,需提前规划维持策略。
局限性
- 研究样本量较小(49人),仅评估低剂量司美格鲁肽(1 mg每周一次)停药后的短期变化,需进一步研究更高剂量及维持获益的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously reported reductions in weight and cardiometabolic risk factors in people with human immunodeficiency virus (PWH) receiving semaglutide; here, we explored the durability of these changes after treatment cessation. METHODS: ACTG A5371 enrolled PWH ≥18 years on suppressive antiretroviral therapy with metabolic dysfunction-associated steatotic liver disease. All received subcutaneous semaglutide 1 mg weekly for 24 weeks followed by 24 weeks off semaglutide. We measured weight and cardiometabolic risk factors (blood pressure, cholesterol, metabolic syndrome) at weeks 0, 24, and 48. Mean (95% confidence interval [CI]) changes were estimated using linear regression. RESULTS: The 49 participants had a median age of 52 years, body mass index 35 kg/m2, 39% Hispanic and 33% Black, and 43% female. After the mean 7.8 kg (95% CI, 6.1-9.5) weight loss in the first 24 weeks, absolute mean weight regain from 24 to 48 weeks was +2.9 kg (95% CI, 1.5-4.3). Weight regain was accompanied by significant increases in waist circumference (2.0 cm [0.9-3.1]) and fasting glucose (5.1 mg/dL [0.9-9.3]) without significant changes in blood pressure, total or low-density lipoprotein cholesterol, triglycerides, or metabolic syndrome. CONCLUSIONS: Short-term, low-dose, semaglutide was associated with cardiometabolic benefit in PWH, but rapid weight regain and some loss of cardiometabolic benefit occurred after stopping semaglutide, similar to the general population. Further study of higher dose semaglutide and strategies to maintain benefits following initial therapy are needed in PWH. ClinicalTrials.gov: NCT04216589.
引用
- Erlandson KM, Kitch DW, Kantor A, et al. The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV. Clin Infect Dis. 2026. PMID: 41299212. doi:10.1093/cid/ciaf652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。